Aramchol Fatty Acid Bile Salt Conjugate Modulating Gut Microbiota
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet medical need for effective treatments that specifically target improving or restoring gut microbiota and alleviating gastrointestinal disorders associated with gut flora imbalance.
Innovation Solution
The use of a pharmaceutical composition comprising a therapeutically effective amount of 3β-arachidylamido-7α, 12α-dihydroxy-5β-cholan-24-oic acid (Aramchol) or its pharmaceutically acceptable salt, which promotes the growth of beneficial microbiota, inhibits detrimental microbiota, enhances microbiota biodiversity, and treats or prevents dysbiosis in the gastrointestinal tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (probiotics, prebiotics, antimicrobial agents) are used to modulate gut microbiota, then some therapeutic benefit may be achieved, but results are inconsistent and often fail to show reliable improvement or even cause aggravation
Solution Approach 1:
The patent changes the chemical parameter of the treatment by using fatty acid bile salt conjugates (FABACs) instead of conventional probiotics, prebiotics, or antimicrobial agents. This chemical class modification enables selective modulation of gut microbiota with more consistent and reliable therapeutic effects, avoiding the aggravation seen with conventional treatments.
2Reliability
If the gut microbiota is targeted for modulation to treat gastrointestinal disorders, then therapeutic effectiveness may be improved, but the field is still in infancy requiring more rigorous studies
Solution Approach 1:
The patent replaces complex mechanical or biological intervention systems (probiotic strains, prebiotic compounds, antimicrobial regimens) with a simpler chemical mechanism - fatty acid bile salt conjugates that directly modulate microbiota composition. This substitution reduces the complexity of the therapeutic approach while maintaining or improving effectiveness.
3Quantity of substance
If existing microbiota modulation approaches are used, then some improvement may be observed, but the composition and diversity of gut microbiota remain difficult to control precisely
Solution Approach 1:
The patent applies local quality by using fatty acid bile salt conjugates that specifically target and modulate particular segments of the gut microbiota composition. This selective modulation allows precise control over which bacterial populations are affected, improving both the quantity and diversity aspects of microbiota control without requiring complex multi-component formulations.
Data Source
AI summary
The present invention is directed to the modulation of gut microbiota. Specifically, the invention relates to pharmaceutical compositions for use in restoring gastrointestinal homeostasis and in alleviating gastrointestinal disorders and other conditions associated with imbalance of gut flora. More specifically, the invention relates to the use of compositions comprising a therapeutically effective amount of a fatty acid bile acid conjugate (FABAC).